Arvinas (NASDAQ:ARVN) had its price objective increased by analysts at BMO Capital Markets from $101.00 to $111.00 in a note issued to investors on Friday, The Fly reports. The firm currently has an "outperform" rating on the stock. BMO Capital Markets' price target points to a potential upside of 20.73% from the company's previous close.
ARVN has been the subject of several other research reports. Zacks Investment Research upgraded shares of Arvinas from a "sell" rating to a "hold" rating in a report on Friday, May 7th. Truist Securities upped their price target on shares of Arvinas from $150.00 to $170.00 and gave the company a "buy" rating in a research report on Thursday. Piper Sandler reissued an "overweight" rating and issued a $105.00 price objective (up from $97.00) on shares of Arvinas in a research note on Thursday. UBS Group assumed coverage on shares of Arvinas in a research note on Thursday, May 20th. They issued a "buy" rating and a $123.00 price objective on the stock. Finally, Truist upped their price target on shares of Arvinas from $150.00 to $170.00 and gave the stock a "buy" rating in a research note on Thursday. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company presently has an average rating of "Buy" and an average target price of $126.13.
ARVN stock traded up $7.43 during trading on Friday, reaching $91.94. 27,799 shares of the stock were exchanged, compared to its average volume of 348,970. The stock has a 50 day simple moving average of $75.26. Arvinas has a 1 year low of $19.68 and a 1 year high of $92.77. The stock has a market cap of $4.50 billion, a price-to-earnings ratio of -28.19 and a beta of 2.00.
Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Monday, May 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.01). The company had revenue of $5.54 million for the quarter, compared to analyst estimates of $3.92 million. Arvinas had a negative net margin of 656.61% and a negative return on equity of 33.38%. Equities analysts expect that Arvinas will post -3.45 earnings per share for the current fiscal year.
In other Arvinas news, CEO John G. Houston sold 700 shares of Arvinas stock in a transaction dated Wednesday, June 9th. The stock was sold at an average price of $80.15, for a total transaction of $56,105.00. Following the transaction, the chief executive officer now owns 828,343 shares of the company's stock, valued at approximately $66,391,691.45. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Ronald Peck sold 20,000 shares of Arvinas stock in a transaction dated Wednesday, June 30th. The shares were sold at an average price of $76.69, for a total value of $1,533,800.00. Following the sale, the insider now owns 22,754 shares of the company's stock, valued at $1,745,004.26. The disclosure for this sale can be found here. 10.99% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its position in Arvinas by 167.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,245,449 shares of the company's stock valued at $190,706,000 after acquiring an additional 1,405,654 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of Arvinas by 125.6% during the first quarter. Point72 Asset Management L.P. now owns 1,128,100 shares of the company's stock valued at $74,567,000 after acquiring an additional 628,100 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Arvinas by 39.7% during the fourth quarter. JPMorgan Chase & Co. now owns 1,612,931 shares of the company's stock valued at $136,986,000 after acquiring an additional 458,362 shares during the period. EcoR1 Capital LLC acquired a new position in Arvinas in the first quarter valued at about $21,066,000. Finally, Wasatch Advisors Inc. acquired a new position in Arvinas in the first quarter valued at about $17,365,000. Institutional investors and hedge funds own 88.12% of the company's stock.
Arvinas Company Profile
Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
Recommended Story: Should I follow buy, hold and sell recommendations?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What is the S&P/TSX Index?7 Stocks to Buy Now and Avoid a Summer Swoon
Summer is generally a quiet time in the markets. Institutional investors, generally speaking, take some time away. In fact, that’s where the idiom “Sell in May and Go Away” comes from.
But quiet doesn’t mean uneventful. The world still moves along even in the lazy months of summer. And at the moment, there are two conflicting views driving the market.
One is the fear that everything’s a bubble that is just about to burst. We don’t recommend you get out of stocks, but let’s face it, things are more than just a little frothy.
But there’s another view summarized by the acronym, YOLO (as in You Only Live Once). And these investors are committed to keeping the markets going higher. Even if it means going “all in” (whatever that means to them) on risky asset classes like NFTs or Dogecoin.
We sincerely hope you take time to recharge (whatever that means to you) this summer. Whatever your personal beliefs, the reopening of our economy is a moment that deserves to be celebrated by all of us. But before you do, we recommend that you take a peek at these seven stocks that you can consider adding to your portfolio before you check out for the summer. These are likely to get as hot as a firecracker on the Fourth of July and should have you smiling when the summer ends.
View the "7 Stocks to Buy Now and Avoid a Summer Swoon"